Achieving universal health coverage (UHC) won’t be possible without paying close attention to one of our most pressing global health threats: drug-resistant infections.
Antimicrobial resistance (AMR) occurs when microorganisms develop resistance to a medicine that was originally intended to disable or kill them. While microbes naturally develop resistance to antimicrobials over time, excessive or inappropriate use of antibiotics speeds up AMR. The issue is a big challenge to UHC, jeopardizing the effectiveness of surgical procedures and threatening the treatment of many infectious diseases, including malaria, tuberculosis, and HIV/AIDS.
According to estimates from The Review on Antimicrobial Resistance, a report commissioned by the U.K. government and the Wellcome Trust, the financial burden from AMR could be as much as USD 100 trillion and the global gross domestic product could decrease 3.5% by 2050. AMR also causes immense loss of life—700,000 people die from drug-resistant infections each year, and this number is expected to grow to 10 million by 2050 if AMR is not contained.